Skip to main content
Menu

Posts tagged with "Business and Markets"

  • Business and Markets

    Two Types of Risk

    It’s the time for the ASCO meeting again, so everyone who follows oncology drug development will be busy catching up on the news. Bruce Booth has a good overview of things here, based on look at the abstracts submitted for the meeting. An analysis of the words mentioned in them shows some interesting features: the… Read More
  • Business and Markets

    Some Side Effect For An Antibody

    Remember back when AstraZeneca was fighting off Pfizer’s ardent, tax-issue-resolving embrace a year ago? One of their weapons was a pitch to their own shareholders about what potential their own pipeline had, and how much of that would presumably go to waste should the deal go through. Even at the time, people thought that their… Read More
  • Business and Markets

    Pfizer Rumors, Again

    Rumors continue to fly around that Pfizer is going to ease its merger hunger and its foreign-cash tax woes by making an offer for GlaxoSmithKline. Lord, what a mess that will be if it happens. Problem is, I can’t completely rule that out. I’m a very poor judge of huge pharma M&A deals, because most… Read More
  • Business and Markets

    Piling On Andrew Witty

    To go along with the recent calls for Andrew Witty to step down at GSK, here’s John LaMattina wondering if he’s the right guy for the job as well: . . .the bigger issue with Witty’s stance is the direction that he is taking GSK. His company has a long and proud history of delivering… Read More
  • Alzheimer's Disease

    An Alzheimer’s IPO, Because Why Not

    Now here’s someone with optimism to burn, compost, and scatter to the winds. According to FierceBiotech, Vivek Ramaswamy has started a company called Axovant Pharmaceuticals, and their asset is a 5-HT6 antagonist from GSK. It goes back to the SmithKline days, when it was known as SB742457. It was in development for Alzheimer’s, apparent… Read More
  • Business and Markets

    Eli Lilly and Cambridge

    So Eli Lilly is opening a research center in Cambridge (specializing in drug delivery). This prompts several questions. Which big drug companies have not taken the Massachusetts Plunge, at least a little bit? (GSK and Roche don’t have much of a presence, to pick two). What finally made Lilly decide that they were missing out… Read More
  • Business and Markets

    A New Old Antibiotic

    Via FierceBiotech, here’s an odd story about a small company you’ve probably never hears of, Symbiomix. They were launched just a couple of years ago, and are now heading into Phase III with an antibiotic. How, you ask, is that remotely possible? Well, it’s an antibiotic (secnidazole, a nitroimidazole) that’s been sold in ot… Read More
  • Business and Markets

    Calls For Andrew Witty’s Job at GSK

    Here you are: a public call for the head of GlaxoSmithKline’s CEO, Andrew Witty: Witty, who’s led Britain’s largest drugmaker since 2008, is facing criticism for Glaxo’s lagging share performance and a depleted pipeline of promising medicines. A bribery scandal in China that led to a $489 million fine last year and sluggish U.S. sales… Read More
  • Business and Markets

    Market Exclusivity Is Sometimes Too Much

    Readers might remember a small company called Catalyst Pharmaceuticals, who have had a business plan that goes something like this: take the known small molecule that’s used for the rare disease Lambert-Eaton Myasthenic Syndrome LEMS, 3,4-diaminopyridine. Rebrand it as “Firdapse”, and do the clinical work needed to get it official… Read More
  • Business and Markets

    Looking Back At Merck/Schering-Plough

    Here’s Ed Silverman Peter Loftus at Pharmalot, looking back at the Merck/Schering-Plough merger. It has not gone quite like the initial plan: First, a little history. In November 2008, Schering-Plough Chief Executive Fred Hassan told analysts and investors gathered at the company’s Kenilworth, N.J., headquarters it was developing “five st… Read More
...202122...